Zydus Lifesciences Ltd

Zydus Lifesciences Gets DCGI Approval for Phase III Trials of Novel Anti-Malarial Drug 🌍💊

• Zydus Lifesciences received DCGI approval on April 25, 2026, to begin Phase III trials for Zintrodiazine.

• The drug is effective against all current clinical strains of P. falciparum and P. vivax, including drug-resistant variants.

• Two Phase III trials will enroll 651 patients for P. falciparum malaria and 390 for P. vivax malaria.

• Trials will assess efficacy (PCR-adjusted ACPR), safety, tolerability, recrudescence, and clearance times.

• Developed in collaboration with Medicines for Malaria Venture (MMV) to combat growing artemisinin resistance.

• Malaria affected over 180,000 people in India last year, underscoring the need for new treatments.

• Zydus employs over 29,000 people globally, including 1,500 scientists dedicated to R&D.